These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [An analysis of 70 patients with bilobectomy for bronchogenic carcinoma].
    Author: Ayabe H, Tochiak H, Oka T, Hara S, Tagawa Y, Kawahara K, Tomita M.
    Journal: Nihon Kyobu Geka Gakkai Zasshi; 1991 Aug; 39(8):1121-5. PubMed ID: 1658164.
    Abstract:
    From 1955 to April 1989, 70 patients underwent bilobectomy for the treatment of primary lung carcinoma. Thirteen patients (18.6%) underwent right upper and middle lobectomy (UML), while 57 patients (81.4%) underwent right middle and lower lobectomy (MML). Indications for bilobectomy were cancer invasion into intermediate bronchus (34%), tumor extending to neighbouring lobe across a fissure (29%), interlobar lymph nodes metastasis with or without invasion to intermediate bronchus (24%), vascular invasion (5%), and others (7%). Squamous cell carcinoma was present in 31 patients, adenocarcinoma in 28, large cell carcinoma in 5, small cell carcinoma in 4 and others in 2. About 60 percent of the patients had Stage III or IV diseases. Postoperative complications occurred in 27 patients (38.6%) and 3 died within 30 days after operation (operative mortality rate. 4.3%). Pneumonia, empyema, atelectasis and arrhythmia were prominent postoperative complications. There were no statistically different postoperative complication rates between those with UML and those of MLL. Five-year survival rate of the patients with bilobectomy for lung cancer was 25.7%, which was between those with single lobectomy (36.9%) and those with pneumonectomy (5.6%). However, there was no statistical difference in 5-year survival rate among operative procedures in each stage.
    [Abstract] [Full Text] [Related] [New Search]